Martin E. Sanders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martin E. Sanders has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Abhijit Mazumdar
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
35 shared publications - Amanda Lanier
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
35 shared publications - Cassandra L. Moyer
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
35 shared publications - Darian Coleman
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
35 shared publications - Jamal Hill
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
35 shared publications - Powel H. Brown
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA
35 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S4: IRX 4204 half-life measurement
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S4: IRX 4204 half-life measurement
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S1: PCR confirmation of the genetically engineered mice used in this manuscript
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S1: PCR confirmation of the genetically engineered mice used in this manuscript
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S9 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S9: Effect of IRX 4204 on splenocytes in Brca1-deficient mice
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S9 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S9: Effect of IRX 4204 on splenocytes in Brca1-deficient mice
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S7 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S7: Effect of IRX 4204 on histopathology and IHC of Ki67, cleaved-caspase 3 and cyclin D1 in MMTV-ErbB2 tumors
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S7 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S7: Effect of IRX 4204 on histopathology and IHC of Ki67, cleaved-caspase 3 and cyclin D1 in MMTV-ErbB2 tumors
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S3: Effect of RXR agonists on body weight and blood parameters from the first Brca1-deficient experiment
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S3: Effect of RXR agonists on body weight and blood parameters from the first Brca1-deficient experiment
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Table S3: Surface and intercellular antibodies used for FACS analysis
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Table S3: Surface and intercellular antibodies used for FACS analysis
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S2: Effect of IRX 4204 on tumor growth
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S2: Effect of IRX 4204 on tumor growth
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Table S1: Description of mouse models
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Table S1: Description of mouse models
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S6: Effect of IRX 4204 on KI-67 in Brca1-deficient mammary glands
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S6: Effect of IRX 4204 on KI-67 in Brca1-deficient mammary glands
- Open Access
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S8: Effect of IRX 4204 on IHC of Ki67 in Brca1-deficient mammary tumors
- 3 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Supplemental Figure S8: Effect of IRX 4204 on IHC of Ki67 in Brca1-deficient mammary tumors